ABBV vs DHR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Danaher Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
AbbVie Inc. · Healthcare
$216.63
+3.8% upside to fair value
Grade C
High Quality
VS
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
DHR trades at a lower forward P/E
(34.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
DHR |
| Current Price |
$216.63 |
$177.17 |
| Fair Value Estimate |
$224.76 |
$192.90 |
| Upside to Fair Value |
+3.8%
|
+8.9%
|
| Market Cap |
$382.7B |
$125.4B |
| Forward P/E |
106.2x
|
34.1x
|
| EV / EBITDA |
26.4x
|
20.8x
|
| Price / Sales |
6.1x
|
5.1x
|
| Price / FCF |
18.3x
|
23.7x
|
| Revenue Growth YoY |
+12.4%
|
+3.7%
|
| Gross Margin |
70.7%
|
60.7%
|
| Operating Margin |
27.6%
|
21.0%
|
| Return on Equity |
68.0%
|
7.1%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.45%
|
4.22%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in pharmaceuticals with a strong focus on immunology, aesthetics, neuroscience, and oncology. The company benefits from a durable competitive moat driven by its immunology franchises, global commercial scale, and R&D capabilities, although it faces challenges from the post-Humira patent cliff and intense competition in biologics and small m…
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
Accumulation Zones
| Metric |
ABBV |
DHR |
| Zone Low |
$168.57 |
$144.68 |
| Zone High |
$191.05 |
$163.97 |
| In Buy Zone? |
No
|
No
|